MedTrace Logo

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

NCT03657745 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-08-01

No results posted yet for this study

Summary

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.

Conditions

Interventions

DEVICE

Combination of 40Hz light and cognitive therapy (ALZLIFE)

Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE

Sponsors & Collaborators

  • Alzheimer's Light LLC

    lead INDUSTRY

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657745 on ClinicalTrials.gov